NCT07291141Recruiting
A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals. A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability. The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk. Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories. The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 5 Dec 2025
- Start date
- 18 Dec 2025
- Primary completion date
- Dec 2029
- Lead sponsor
- Mattias Ekstedt
- NCT number
- NCT07291141
What you commit to
- Study type: Observational
- Planned participants: 600
- From 18 Dec 2025 to the primary completion date, Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous diagnosis of hepatic carcinoma (HCC)
- Previous liver transplant
Other illness
- Vascular liver disease
Other
- Contraindications for MRI (ferrrous material, claustrophobia)
- Pregnancy
- Diagnosis of primary sclerosing cholangitis (PSC)
- Congenital liver fibrosis
Who the study is looking for
- Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology.
- Age ≥18 years ≤ 84
- Written informed consent from the participant
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of gastroenterology and hepatology, University hospital in Linköping Coordinator of this site? Confirm its status | Linköping | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.